Evaluation of the Effect of Haloperidol, Risperidone, and Quetiapine in the Delirium of Cancer Patients

Evaluation and Comparison of the Effect of Haloperidol, Risperidone, and Quetiapine Medications in the Treatment of Delirium in End-stage Cancer Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190404043159N3

Enrollment

Registered

2021-04-02

Start date

2020-09-22

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Delirium. Condition 2: Malignancy. Delirium due to known physiological condition Malignant (primary) neoplasm, unspecified

Interventions

Intervention 1: First Intervention group: Abidi's haloperidol tablets (1-6 mg daily) starting with the minimum dose and increasing daily until the delirium symptoms improve or the drug dose is reached

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of any Type of End-stage Cancer Informed Consent of the Patient or Family More than 18 Years Old Diagnosis o Delirium Disorder According to DSM-V Criterion

Exclusion criteria

Exclusion criteria: Presence of Major Neurocognitive Disorder Contraindication for Consumption of Antipsychotic Medications

Design outcomes

Primary

Measure	Time frame
Delirium Score in Intensive Care Delirium Screening Checklist. Timepoint: Before the intervention and daily for up to 7 days after remission. Method of measurement: Intensive Care Delirium Screening Checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Sharbafchi

Esfahan University of Medical Sciences

sharbafchi@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026